過氧化物酶體增殖物激活受體γ(PPARg)多克隆抗體
Polyclonal Antibody to Peroxisome Proliferator Activated Receptor Gamma (PPARg)
PPAR-G; PPARG1; PPARG2; NR1C3; Glitazone Receptor; Nuclear Receptor Subfamily 1 Group C Member 3
- 編號(hào)UPAA886Mu03
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 來源多抗制備
- 宿主兔
- 效價(jià)-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無標(biāo)記物
- 免疫原 RPA886Mu03-過氧化物酶體增殖物激活受體γ(PPARg)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度0.5mg/mL
- 且適物種-
- 應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 294 ¥ 687 ¥ 981 ¥ 2453 ¥ 9810
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)PPARg的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別PPARg。
用法
Western blotting: 0.01-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA886Mu03 | 過氧化物酶體增殖物激活受體γ(PPARg)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA886Mu01 | 過氧化物酶體增殖物激活受體γ(PPARg)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA886Mu02 | 過氧化物酶體增殖物激活受體γ(PPARg)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA886Mu03 | 過氧化物酶體增殖物激活受體γ(PPARg)多克隆抗體 | WB; IHC; ICC; IP. |
| UPAA886Mu02 | 過氧化物酶體增殖物激活受體γ(PPARg)多克隆抗體 | WB; ICC/IF |
| UPAA886Mu01 | 過氧化物酶體增殖物激活受體γ(PPARg)多克隆抗體 | WB |
| UFAA886Mu01 | 抗過氧化物酶體增殖物激活受體γ(PPARg)多克隆抗體 | FCM |
| UFAA886Mu03 | 抗過氧化物酶體增殖物激活受體γ(PPARg)多克隆抗體 | FCM |
| ULAA886Mu71 | 過氧化物酶體增殖物激活受體γ(PPARg)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| USEA886Mu | 過氧化物酶體增殖物激活受體γ(PPARg)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA886Mu | 過氧化物酶體增殖物激活受體γ(PPARg)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UKSA886Mu01 | 過氧化物酶體增殖物激活受體γ(PPARg)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Neuroscience Letters | Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosis [Pubmed: 24021801] |
| J Cell Biochem. | Nonivamide enhances miRNA let‐7d expression and decreases adipogenesis PPARγ expression in 3T3‐L1 cells [Pubmed:25704235] |
| Osteoarthritis Cartilage | Establishment of a rabbit model to study the influence of advanced glycation end products accumulation on osteoarthritis and the protective effect of pioglitazone [PubMed: 26321377] |
| J Clin Diagn Res. | Evaluation of Protein Kinase Cβ and PPARγ Activity in Diabetic Rats Supplemented with Momordica charantia [pmc:PMC4866090] |
| Journal of Clinical&Diagnostic Research | Evaluation?of?Protein?Kinase?Cβ and PPARγ?Activity?in?Diabetic?RatsSupplemented?with?Momordica?charantia. [pubmed:27190792] |
| Osteoarthritis?and?Cartilage | Establishment?of a?rabbit?model?to?study?the?influence?of?advanced?glycation?end?productsaccumulation?on?osteoarthritis?and the?protective?effect?of pioglitazone. [pubmed:26321377] |
| Neuroscience Letters | Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosis [pubmed:28483651] |
| European?Journal?of?Immunology | Engulfment of Hb‐activated platelets differentiates monocytes into pro‐inflammatory macrophages in PNH patients [Pubmed:29677388] |
| Histochemistry and?Cell Biology | Simpson–Golabi–Behmel syndrome human adipocytes reveal a changing phenotype throughout differentiation [Pubmed:29574488] |
| molecular and cellular biochemistry | Maternal omega-3 fatty acids and vitamin E improve placental angiogenesis in late-onset but not early-onset preeclampsia [Pubmed: 31420792] |
| Nutrients.? | Hyperglycemia Changes Expression of Key Adipogenesis Markers (C/EBPα and PPAR?) and Morphology of Differentiating Human Visceral Adipocytes [Pubmed: 31398873] |
| journal of biochemical and molecular toxicology | Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cells [Pubmed: 31916655] |
| J Cosmet Dermatol | In?\vitro effect of pine bark extract on melanin synthesis, tyrosinase activity, production of endothelin?\1 and PPAR in cultured melanocytes exposed to Ultraviolet??- [33960120] |
| American Chemical Society | TRPA1 Agonist Cinnamaldehyde Decreases Adipogenesis in 3T3-L1 Cells More Potently than the Non-agonist Structural Analog Cinnamyl Isobutyrate [33403292] |
| PLoS One | Quantitative real-time measurement of endothelin-1-induced contraction in single non-activated hepatic stellate cells [34343209] |
| Prostaglandins Leukot Essent Fatty Acids | Maternal Vitamin D Deficiency Reduces Docosahexaenoic Acid, Placental Growth Factor and Peroxisome Proliferator Activated Receptor Gamma levels in the Pup?… [34768025] |
| Food and Chemical Toxicology | Melatonin attenuates cisplatin-induced acute kidney injury in mice: Involvement of PPARα and fatty acid oxidation [Pubmed:35367536] |
